Table 3.
Summary of functional attributes for ABP 215, bevacizumab (US), and bevacizumab (EU).
| Analytical Testing/Attributes | ABP 215 Range (n) | Bevacizumab US Range (n) | Bevacizumab EU Range (n) |
|---|---|---|---|
| Inhibition of proliferation (potency) (%) | 91–105 (13) | 86–104 (24) | 88–103 (25) |
| Relative VEGF-A binding (%) | 84–98 (13) | 80–104 (14) | 76–99 (13) |
| VEGF-A binding affinity (KD) | 20.1–23.5 (3) | 22.9–23.9 (3) | 18.4–23.4 (3) |
| Binding to FcRn (%) | 84–104 (13) | 91–107 (14) | 88–103 (14) |
| Binding to FcγRIa (%) | 90–98 (3) | 83–90 (3) | 99–102 (3) |
| Binding to FcγRIIa (%) | 83–101 (3) | 89–91 (3) | 80–90 (3) |
| Binding to FcγRIIb (%) | 92–98 (3) | 90–94 (3) | 87–91 (3) |
| Binding to FcγRIIIa, 158V (%) | 78–115 (13) | 77–98 (12) | 81–117 (17) |
| Binding to FcγRIIIa, 158F (%) | 84–120 (13) | 80–110 (10) | 83–109 (10) |
| Binding to FcγRIIIb (%) | 89–92 (3) | 80–85 (3) | 67–88 (3) |
| Binding to C1q (%) | 91–122 (13) | 88–115 (10) | 90–104 (9) |
n indicates a number of samples tested